Treatment interruptions and regimen changes in first-generation vs. second-generation tyrosine kinase inhibitors used as first-line therapy for chronic myeloid leukemia
Citation
Ward, M., Fang, G., Richards, K., Walko, C., Earnshaw, S., & Happe, L. (2015). Treatment interruptions and regimen changes in first-generation vs. second-generation tyrosine kinase inhibitors used as first-line therapy for chronic myeloid leukemia. Journal of Health Economics, 2(2), 181-91.